Shane D. Gilligan-Steinberg

Shane D. Gilligan-Steinberg

Auto-generated profile, based on publicly available information

Shane D. Gilligan-Steinberg

Department of Bioengineering, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Science Advances
Verified
Journal Article
Open access
NPNuttada Panpradist
Nuttada Panpradist
EKEnos C. Kline
Enos C. Kline
RARobert G. Atkinson
Robert G. Atkinson
MRMichael Roller
Michael Roller
QWQin Wang
Qin Wang
BLBarry Lutz
Barry Lutz
A unique four-plexed RT-LAMP test kit operated by health workers can provide faster, more sensitive results than laboratory tests.

1 April 2024 in Analytica Chimica Acta
Verified
Journal Article
Closed access
QWQin Wang
Qin Wang
SGShane D. Gilligan-Steinberg
Shane D. Gilligan-Steinberg
WKWookyeom Kim
Wookyeom Kim
EKEnos C. Kline
Enos C. Kline
IHIan T. Hull
Ian T. Hull
BLBarry Lutz
Barry Lutz

8 April 2026 in Nature
Verified
Journal Article
Open access
JSJaclyn E. Smith
Jaclyn E. Smith
KWKevin J. Wang
Kevin J. Wang
EKErin M. Kennedy
Erin M. Kennedy
JMJane C. Munday
Jane C. Munday
LSLulu Singer
Lulu Singer
MMMonica R. Mugnier
Monica R. Mugnier
Antigenic variation, using large genomic repertoires of antigen-encoding genes, allows pathogens to evade host antibody. Many pathogens, including the African trypanosome Trypanosoma brucei , extend their antigenic repertoire through genomic diversification. Although evidence suggests that T. brucei depends on the generation of new variant surface glycoprotein (VSG) genes to maintain a chronic infection 1–4 , a lack of experimentally tractable tools for studying this process has obscured its underlying mechanisms. Here we present a highly sensitive targeted sequencing approach for measuring VSG diversification. Using this method, we demonstrate that a Cas9-induced DNA double-strand break within the VSG coding sequence can induce RAD51- and BRCA2-dependent VSG recombination with patterns identical to those observed during infection. These newly generated VSGs are antigenically distinct from parental clones and thus capable of facilitating immune evasion. Together, these results provide insight into the mechanisms of VSG diversification and an experimental framework for studying the evolution of antigen repertoires in pathogenic microorganisms.

13 February 2025 in Analytical Chemistry
Verified
Journal Article
Closed access
SGShane D. Gilligan-Steinberg
Shane D. Gilligan-Steinberg
EKEnos C. Kline
Enos C. Kline
QWQin Wang
Qin Wang
RBRhett J. Britton
Rhett J. Britton
WKWookyeom Kim
Wookyeom Kim
BLBarry Lutz
Barry Lutz

17 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CBCara Brainerd
Cara Brainerd
MSMaya Abigail Singh
Maya Abigail Singh
JTJohn Tatka
John Tatka
CCCosette Craig
Cosette Craig
SGShane Gilligan-Steinberg
Shane Gilligan-Steinberg
AOAyokunle Olanrewaju
Ayokunle Olanrewaju
Maintaining adequate levels of antiretroviral (ARV) medications is crucial for the efficacy of HIV treatment and prevention regimens. Monitoring ARV levels can predict or prevent adverse health outcomes like treatment failure or drug resistance. However, conventional ARV measurement using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is slow, expensive, and centralized delaying clinical and behavioral interventions. We previously developed a rapid enzymatic assay for measuring nucleotide reverse transcriptase inhibitors (NRTIs) — the backbone of HIV treatment and prevention regimens — based on the drugs' termination of DNA synthesis by HIV reverse transcriptase (RT) enzyme. Here we expand our work to include non-nucleoside reverse transcriptase inhibitors (NNRTIs) — an ARV class used in established and emerging HIV treatment and prevention regimens. We demonstrate that the REverse Transcriptase ACTivity (REACT) assay can detect NNRTIs including medications used in oral and long-acting/extended-release HIV treatment and prevention. We demonstrate that REACT can measure NNRTIs spiked in either buffer or diluted plasma, and that fluorescence can be measured on both a traditional plate reader and an inexpensive portable reader that can be deployed in point-of-care (POC) settings. REACT measured clinically relevant concentrations of five NNRTI spiked in aqueous buffer. REACT measurements showed excellent agreement between the plate reader and the portable reader, with a high correlation in both aqueous buffer (Pearson's r=0.9807, P < 0.0001) and diluted plasma (Pearson's r = 0.9681, P < 0.0001). REACT has the potential to provide rapid measurement of NNRTIs in POC settings and may help to improve HIV treatment and prevention outcomes.

1 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
QWQin Wang
Qin Wang
EKEnos C. Kline
Enos C. Kline
SGShane D. Gilligan-Steinberg
Shane D. Gilligan-Steinberg
JLJames J. Lai
James J. Lai
IHIan T. Hull
Ian T. Hull
BLBarry Lutz
Barry Lutz
Pathogens encapsulate or encode their own suite of enzymes to facilitate replication in the host. The pathogen-derived enzymes possess specialized activities that are essential for pathogen replication and have naturally been candidates for drug targets. Phenotypic assays detecting the activities of pathogen-derived enzymes and characterizing their inhibition under drugs offer an opportunity for pathogen detection, drug resistance testing for individual patients, and as a research tool for new drug development. Here, we used HIV as an example to develop assays targeting the reverse transcriptase (RT) enzyme encapsulated in HIV for sensitive detection and phenotypic characterization, with the potential for point-of-care (POC) applications. Specifically, we targeted the complementary (cDNA) generation activity of the HIV RT enzyme by adding engineered RNA as substrates for HIV RT enzyme to generate cDNA products, followed by cDNA amplification and detection facilitated by loop-mediated isothermal amplification (LAMP) or CRISPR-Cas systems. To guide the assay design, we first used qPCR to characterize the cDNA generation activity of HIV RT enzyme. In the LAMP-mediated Product-Amplified RT activity assay (LamPART), the cDNA generation and LAMP amplification were combined into one pot with novel assay designs. When coupled with direct immunocapture of HIV RT enzyme for sample preparation and endpoint lateral flow assays for detection, LamPART detected as few as 20 copies of HIV RT enzyme spiked into 25μL plasma (fingerstick volume), equivalent to a single virion. In the Cas-mediated Product-Amplified RT activity assay (CasPART), we tailored the substrate design to achieve a LoD of 2e4 copies (1.67fM) of HIV RT enzyme. Furthermore, with its phenotypic characterization capability, CasPART was used to characterize the inhibition of HIV RT enzyme under antiretroviral drugs and differentiate between wild-type and mutant HIV RT enzyme for potential phenotypic drug resistance testing. Moreover, the CasPART assay can be readily adapted to target the activity of other pathogen-derived enzymes. As a proof-of-concept, we successfully adapted CasPART to detect HIV integrase with a sensitivity of 83nM. We anticipate the developed approach of detecting enzyme activity with product amplification has the potential for a wide range of pathogen detection and phenotypic characterization.